Literature DB >> 11479741

A molecular approach to dominance in hypophosphatasia.

A S Lia-Baldini1, F Muller, A Taillandier, J F Gibrat, M Mouchard, B Robin, B Simon-Bouy, J L Serre, A S Aylsworth, E Bieth, S Delanote, P Freisinger, J C Hu, H P Krohn, M E Nunes, E Mornet.   

Abstract

Hypophosphatasia is an inherited disorder characterized by defective bone mineralization and a deficiency of tissue-nonspecific alkaline phosphatase (TNSALP) activity. The disease is highly variable in its clinical expression, because of various mutations in the TNSALP gene. In approximately 14% of the patients tested in our laboratory, only one TNSALP gene mutation was found, despite exhaustive sequencing of the gene, suggesting that missing mutations are harbored in intron or regulatory sequences or that the disease is dominantly transmitted. The distinction between these two situations is of importance, especially in terms of genetic counseling, but dominance is sometimes difficult to conclusively determine by using familial analysis since expression of the disease may be highly variable, with parents of even severely affected children showing no or extremely mild symptoms of the disease. We report here the study of eight point mutations (G46 V, A99T, S164L, R167 W, R206 W, G232 V, N461I, I473F) found in patients with no other detectable mutation. Three of these mutations, G46 V, S164L, and I473F, have not previously been described. Pedigree and/or serum alkaline phosphatase data suggested possible dominant transmission in families with A99T, R167 W, and G232 V. By means of site-directed mutagenesis, transfections in COS-1 cells, and three-dimensional (3D) modeling, we evaluated the possible dominant effect of these eight mutations. The results showed that four of these mutations (G46 V, A99T, R167 W, and N461I) exhibited a negative dominant effect by inhibiting the enzymatic activity of the heterodimer, whereas the four others did not show such inhibition. Strong inhibition resulted in severe hypophosphatasia, whereas partial inhibition resulted in milder forms of the disease. Analysis of the 3D model of the enzyme showed that mutations exhibiting a dominant effect were clustered in two regions, viz., the active site and an area probably interacting with a region having a particular biological function such as dimerization, tetramerization, or membrane anchoring.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479741     DOI: 10.1007/s004390100546

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  26 in total

1.  Rare coding variants in ALPL are associated with low serum alkaline phosphatase and low bone mineral density.

Authors:  Carrie M Nielson; Joseph M Zmuda; Amy S Carlos; Wendy J Wagoner; Emily A Larson; Eric S Orwoll; Robert F Klein
Journal:  J Bone Miner Res       Date:  2012-01       Impact factor: 6.741

2.  Clinical utility gene card for: hypophosphatasia.

Authors:  Etienne Mornet; Christine Beck; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2010-10-27       Impact factor: 4.246

3.  Clinical utility gene card for: hypophosphatasia - update 2013.

Authors:  Etienne Mornet; Christine Hofmann; Agnès Bloch-Zupan; Hermann Girschick; Martine Le Merrer
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

4.  5-Oxoprolinuria in Heterozygous Patients for 5-Oxoprolinase (OPLAH) Missense Changes.

Authors:  Eduardo Calpena; Mercedes Casado; Dolores Martínez-Rubio; Andrés Nascimento; Jaume Colomer; Eva Gargallo; Angels García-Cazorla; Francesc Palau; Rafael Artuch; Carmen Espinós
Journal:  JIMD Rep       Date:  2012-07-06

5.  Molecular defect of tissue-nonspecific alkaline phosphatase bearing a substitution at position 426 associated with hypophosphatasia.

Authors:  Hiba A Al-Shawafi; Keiichi Komaru; Kimimitsu Oda
Journal:  Mol Cell Biochem       Date:  2016-12-20       Impact factor: 3.396

6.  Molecular diagnosis of hypophosphatasia and differential diagnosis by targeted Next Generation Sequencing.

Authors:  Agnès Taillandier; Christelle Domingues; Clémence De Cazanove; Valérie Porquet-Bordes; Sophie Monnot; Tina Kiffer-Moreira; Agnès Rothenbuhler; Pascal Guggenbuhl; Catherine Cormier; Geneviève Baujat; Françoise Debiais; Yline Capri; Martine Cohen-Solal; Philippe Parent; Jean Chiesa; Anne Dieux; Florence Petit; Joelle Roume; Monica Isnard; Valérie Cormier-Daire; Agnès Linglart; José Luis Millán; Jean-Pierre Salles; Christine Muti; Brigitte Simon-Bouy; Etienne Mornet
Journal:  Mol Genet Metab       Date:  2015-09-30       Impact factor: 4.797

7.  Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia.

Authors:  Lothar Seefried; Jasmin Baumann; Sarah Hemsley; Christine Hofmann; Erdmute Kunstmann; Beate Kiese; Yue Huang; Simon Chivers; Marie-Anne Valentin; Babul Borah; Ronenn Roubenoff; Uwe Junker; Franz Jakob
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

8.  Hypophosphatasia may lead to bone fragility: don't miss it.

Authors:  Pierre Moulin; Frédéric Vaysse; Eric Bieth; Etienne Mornet; Isabelle Gennero; Sara Dalicieux-Laurencin; Christiane Baunin; Marie Thérèse Tauber; Jérôme Sales De Gauzy; Jean Pierre Salles
Journal:  Eur J Pediatr       Date:  2008-09-26       Impact factor: 3.183

9.  A new mechanism of dominance in hypophosphatasia: the mutated protein can disturb the cell localization of the wild-type protein.

Authors:  A S Lia-Baldini; I Brun-Heath; C Carrion; B Simon-Bouy; J L Serre; M E Nunes; E Mornet
Journal:  Hum Genet       Date:  2008-03-14       Impact factor: 4.132

10.  Mild forms of hypophosphatasia mostly result from dominant negative effect of severe alleles or from compound heterozygosity for severe and moderate alleles.

Authors:  Delphine Fauvert; Isabelle Brun-Heath; Anne-Sophie Lia-Baldini; Linda Bellazi; Agnès Taillandier; Jean-Louis Serre; Philippe de Mazancourt; Etienne Mornet
Journal:  BMC Med Genet       Date:  2009-06-06       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.